• Citer

Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop.

par Moreland, Nicole J;Waddington, Claire S;Williamson, Deborah A;Sriskandan, Shiranee;Smeesters, Pierre ;Proft, Thomas;Steer, Andrew C;Walker, Mark J;Baker, Edward N;Baker, Michael G;Lennon, Diana;Dunbar, Rod;Carapetis, Jonathan Rhys;Fraser, John D
Référence Vaccine, 32, 30, page (3713-3720)
Publication Publié, 2014-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domain (J8 vaccine) were reviewed together with vaccine candidates identified using multi high-throughput approaches. Performing a comprehensive assessment of regional GAS strain epidemiology, defining the immune correlates of protection, and the establishment of clinical trial sites were identified as critical activities for a Trans-Tasman vaccine development programme.